Fierce Pharma

JULY 11, 2024

Even as pharma companies have yet to feel the full effects of the Inflation Reduction Act, Senate lawmakers have turned their attention to another facet of drug pricing with a bill meant to cr | The bill looks to limit the number of patents that companies can assert in litigation on individual products.

Pharma 298

Pharma Competition 298

MedCity News

AUGUST 12, 2024

FDA approval of Ascendis Pharma’s Yorvipath is just in time for patients with hypoparathyroidism as Takeda Pharmaceutical will soon stop making the only drug therapy for the rare disorder. But competition could come from others, including an AstraZeneca peptide in late-stage development.

FDA 304

FDA Pharma Competition Pharmaceutical 304

MedCity News

FEBRUARY 6, 2024

However, the Phase 2 results showed only “clinically meaningful” improvement in resolving liver fibrosis, a key measure of the drug’s potential competitiveness in a crowded field of contenders. Eli Lilly reported 74% of patients treated with tirzepatide achieved resolution of metabolic dysfunction-associated steatohepatitis, or MASH.

Competition 306

Competition Patients Biopharma Pharma 306

MedCity News

DECEMBER 4, 2024

The results could help Lilly differentiate its product from Novo Nordisk’s in the increasingly competitive market of obesity medications. Eli Lilly obesity drug Zepbound led to 47% greater relative weight loss compared to Wegovy in a head-to-head clinical trial.

Leads 296

Leads Competition Medical Marketing 296

Fierce Pharma

MARCH 10, 2023

Pfizer hopes to nose out competition with approval for new migraine nasal spray Zavzpret kdunleavy Fri, 03/10/2023 - 10:22

Competition 293

Competition 293

MedCity News

JANUARY 22, 2024

If Ionis can commercialize this drug, competition would include products from Takeda Pharmaceutical and BioCryst Pharmaceuticals. In its Phase 3 test, Ionis Pharmaceuticals drug donidalorsen reduced the frequency of swelling attacks caused by the rare disease hereditary angioedema.

Competition 293

Competition Pharmaceutical FDA Biopharma 293

Fierce Pharma

OCTOBER 30, 2024

Baxter plans to exit China's IV fluids market as it faces tough local competition and as it redirects global IV supplies to the U.S. Baxter International plans to exit China’s intravenous fluids market, multiple local media outlets report, citing a letter to distributors. to cope with a post-hurricane shortage.

Competition 238

Competition Marketing Media 238

MedCity News

FEBRUARY 23, 2023

FDA approval of Sanofi hemophilia A drug Altuviiio provides patients with a therapeutic option that lasts longer than most other products available, including one already marketed by the French pharma giant. Altuviiio also gives Sanofi a way to better compete against blockbuster Roche drug Hemlibra.

Competition 276

Competition FDA Patients Pharma 276

MedCity News

NOVEMBER 26, 2024

While investors hoped for greater weight loss, some analysts say less burdensome monthly dosing of MariTide could make it competitive against weekly injectable weight drugs Zepbound and Wegovy. Amgen’s experimental obesity drug, MariTide, led to an average 20% reduction in weight in a Phase 2 clinical trial.

Competition 319

Competition Biopharma Pharma 319

Fierce Pharma

OCTOBER 25, 2024

On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more competition in the space is a net positive. . | Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus antibody clesrovimab, Sanofi thinks Beyfortus can hold its own.

Competition 231

Competition Sales 231

MedCity News

AUGUST 17, 2022

The move means Sanofi is out of the competitive chase to develop a so-called “oral SERD” therapy for patients with a certain type of breast cancer. Sanofi breast cancer drug amcenestrant has failed in a Phase 3 clinical trial, leading the pharmaceutical giant to discontinue all clinical development of the small molecule.

Competition 246

Competition Leads Pharmaceutical Patients 246

Fierce Pharma

DECEMBER 1, 2023

Turkish authorities have launched an investigation into 19 pharmaceutical companies to probe whether their operations violated the country’s competition law, the Turkish Competition Authority discl | The companies, which include Pfizer, J&J, Sanofi, AbbVie, AstraZeneca, Merck and others are being probed for potentially violating Turkish competition (..)

Competition 224

Competition Government Pharmaceutical 224

World of DTC Marketing

JULY 22, 2021

The culture within pharma is driving people away, including new hires. Age discrimination within pharma is real. With the loss of more experienced people, the pharma industry is losing talent and gaining what? On Quora, there was a discussion about working within pharma s a recent MBA grad wanted the pros and cons.

Pharma 309

Pharma Marketing Ethics Patients 309

MedCity News

DECEMBER 27, 2023

Cytokinetics drug aficamten met the main goal of a pivotal test in obstructive hypertrophic cardiomyopathy. If approved, the daily pill would compete against a Bristol Myers Squibb drug projected to become a blockbuster seller.

Competition 320

Competition Biopharma Pharma 320

MedCity News

NOVEMBER 7, 2023

Such listings delay generic competition, which reduces consumer choice and keeps prices high, the regulator said. The Federal Trade Commission says more than 100 patents from 10 biopharma companies are improperly listed in the FDA’s official publication of approved products.

Biopharma 338

Biopharma Competition FDA Pharma 338

MedCity News

JUNE 16, 2023

The FDA approved Roche’s Columvi as a third-line treatment for a type of blood cancer called diffuse large B-cell lymphoma. This new Roche drug will compete against Epkinly, AbbVie’s recently approved DLBCL drug.

Competition 296

Competition FDA Biopharma Pharma 296

Fierce Pharma

JULY 11, 2023

The race for competitive advantage for pharma today is about far more than just innovative new molecules.

Competition 144

Competition Pharma Marketing Patients 144

Fierce Pharma

OCTOBER 3, 2024

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, | Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, freeing the company from competing with compounding pharmacies that have been producing copycat versions of the (..)

Competition 292

Competition 292

MedCity News

MAY 10, 2023

A drug developed by Protalix BioTherapeutics and Chiesi Group is now FDA approved for treating Fabry disease, a rare inherited metabolic disorder. The drug, Elfabrio, is an enzyme replacement therapy.

Competition 285

Competition FDA Biopharma Pharma 285

Fierce Pharma

OCTOBER 19, 2023

In the race for leadership in the treatment of early-stage non-small cell lung cancer (NSCLC), Bristol Myers Squibb has put up trial data that look competitive to those from Merck’s Keytruda. | But a key debate remains unsettled.

Competition 189

Competition 189

MedCity News

SEPTEMBER 29, 2023

Preliminary weight loss and safety data for Structure Therapeutics’ drug candidate suggest it’s competitive with other oral GLP-1 targeting contenders from big pharma companies.

Competition 308

Competition Safety Pharma Biopharma 308

MedCity News

JANUARY 28, 2024

While pharmaceutical companies continue to raise list prices year-over-year, we work behind the scenes to fight the trend by driving competition, negotiating with drugmakers and incentivizing the use of less expensive medicines that deliver the same clinical value.

Competition 324

Competition Medicine Pharma Patients 324

MedCity News

JULY 19, 2023

The restructuring of cardiovascular drugmaker Amarin means the layoff of about 30% of staff. Sales of Vascepa, the company’s only commercialized product, have suffered as generic versions gain traction in the market.

Competition 245

Competition Sales Marketing Biopharma 245

World of DTC Marketing

APRIL 20, 2022

We just finished talking to over 200 hundred HCPs about pharma marketing and salespeople to measure any differences since before the pandemic. This was especially true with new drugs that have a significant competitive market. Pharma websites are a resource, but they don’t provide what they need and want to prescribe the drug.

Marketing 218

Marketing Pharma Insurance Medical 218

PharmaVoice

AUGUST 28, 2023

In the high-growth but competitive field of migraine treatments, CGRP drugs have changed the game — but the search is still on for more options.

Pharma 244

Pharma Competition 244

MedCity News

DECEMBER 13, 2022

Amgen’s Lumakras became the first FDA-approved drug that addresses the elusive KRAS mutation, but Mirati believes its newly approved therapy, Krazati, could be better. The small molecule’s features include the ability to penetrate into the brain, where it can address cancer that has spread to the central nervous system.

Competition 276

Competition FDA Biopharma Pharma 276

Pharma Marketing Network

MARCH 12, 2025

Unlike consumer brands that can use aggressive bidding strategies on high-volume keywords, pharma ads must navigate strict regulatory guidelines. For an in-depth look at how pharma companies succeed in digital advertising, visit Pharma Marketing Network. Understanding Pharma-Specific PPC Challenges 1.

Marketing 59

Marketing Pharma Prescription Competition 59

MedCity News

JANUARY 23, 2023

The FDA approved TheracosBio’s Brenzavvy as a treatment for type 2 diabetes. But before it won a regulatory nod for controlling blood glucose in adults, it was approved at a different dose (with flavor) as a veterinary product.

Competition 246

Competition FDA Biopharma Pharma 246

MedCity News

JUNE 26, 2023

Pfizer’s Litfulo is the first treatment approved for treating adolescents with severe alopecia areata. The drug’s approval also covers adults, were it will compete against Eli Lilly’s Olumiant.

Competition 263

Competition FDA Biopharma Pharma 263

MedCity News

FEBRUARY 26, 2024

Preliminary Phase 2 results show 83% of those treated with Boehringer Ingelheim and Zealand Pharma drug survodutide met the main goal of improvement in the fatty liver disease MASH. Boehringer contends this drug has best-in-class potential in a competitive field that includes an Eli Lilly drug that recently posted positive Phase 2 results.

Competition 276

Competition Pharma Biopharma 276

World of DTC Marketing

NOVEMBER 9, 2021

SUMMARY: Quantitative and qualitative data was gained through surveys with EPG Health’s multi-stakeholder databases (HCP, pharma, and service providers) and interviews conducted with pharma execs by Impatient Health. Key Findings 1 : HCPS ARE IN CONTROL AND PHARMA KNOWS IT. Pharma must level up the value they deliver.

Pharma 231

Pharma Medical Education Media 231

World of DTC Marketing

JUNE 7, 2021

The true risk to pharma in response to unacceptable drug pricing may come from growing bipartisan support to increase industry antitrust scrutiny and penalties. Eight US antitrust bills targeting the pharmaceutical industry have been recently introduced, addressing a gamut of alleged anti-competitive activity. AARP Drug Pricing.

Pharma 187

Pharma Retail Competition Prescription 187

PharmaVoice

DECEMBER 18, 2024

The pharma giant is looking for another edge in the competitive weight loss market through DTC expansion.

Competition 231

Competition Pharma Marketing 231

Pharma Marketing Network

MARCH 18, 2025

Introduction Climbing the ladder in marketing pharma requires more than just technical skills. The pharmaceutical industry is competitive, fast-paced, and highly regulated, making it essential for marketers to stay ahead of trends, build strong industry relationships, and continuously improve their strategic thinking.

Marketing 52

Marketing Pharma Networking Media 52

Fierce Pharma

JULY 12, 2024

Several challenges across Bristol Myers Squibb’s business have Leerink Partners analysts worried about the future—despite a few promising growth opportunities the team has identified.

Competition 229

Competition 229

Fierce Pharma

NOVEMBER 11, 2024

Watch out, Gilead and Novartis: there's a new CAR-T in town. Autolus' Aucatzyl has become the first CAR-T approved by the FDA without a REMS mandate. And the company is ready to hit the ground running, facing Gilead and Novartis as its competitors.

Competition 243

Competition FDA 243

Pharma Marketing Network

MARCH 24, 2025

In a world where innovation, regulation, and consumer behavior shift rapidly, keeping up with pharma news is not just helpfulits essential. For pharma marketing executives and their teams, staying current helps maintain competitive advantage, ensures compliance, and unlocks opportunities for smarter, faster campaign decisions.

Marketing 52

Marketing Pharma Networking Media 52